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Objective: To characterize the post-expansion cartilage-forming capacity of chondrocytes harvested from
detached fragments of osteochondral lesions (OCLs) of ankle joints (Damaged Ankle Cartilage Fragments,
DACF), with normal ankle cartilage (NAC) as control.
Design: DACF were obtained from six patients (mean age: 35years) with symptomatic OCLs of the talus,
while NAC were from 10 autopsies (mean age: 55 years). Isolated chondrocytes were expanded for two
passages and then cultured in pellets for 14 days or onto HYAFF-11 meshes (FAB, Italy) for up to 28 days.
Resulting tissues were assessed histologically, biochemically [glycosaminoglycan (GAG), DNA and type II
collagen (CII)] and biomechanically.
Results: As compared to NAC, DACF contained signiﬁcantly lower amounts of DNA (3.0-fold), GAG (5.3-
fold) and CII (1.5-fold) and higher amounts of type I collagen (6.2-fold). Following 14 days of culture in
pellets, DACF-chondrocytes generated tissues less intensely stained for Safranin-O and CII, with signif-
icantly lower GAG contents (2.8-fold). After 28 days of culture onto HYAFF-11, tissues generated by
DACF-chondrocytes were less intensely stained for Safranin-O and CII, contained signiﬁcantly lower
amounts of GAG (1.9-fold) and CII (1.4-fold) and had lower equilibrium (1.7-fold) and dynamic pulsatile
modulus (3.3-fold) than NAC-chondrocytes.
Conclusion: We demonstrated that DACF-chondrocytes have inferior cartilage-forming capacity as
compared to NAC-chondrocytes, possibly resulting from environmental changes associated with trauma/
disease. The study opens some reservations on the use of DACF-derived cells for the repair of ankle
cartilage defects, especially in the context of tissue engineering-based approaches.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
For chondral and osteochondral lesions (OCLs) of the talus
(ankle joint), different cell-based therapies such as the autologous
chondrocyte transplantation (ACT) and matrix associated ACT are
established operative procedures1e3. For these procedures, chon-
drocytes are commonly harvested from the healthy and not
affected knee joint3e5. However, a cartilage biopsy in a joint, even ifAndrea Barbero, Institute for
Hospital Basel, Hebelstrasse
1-265-2379; Fax: 41-61-265-
s Research Society International. Pharvested from a non-load bearing site, represents an additional
injury to the cartilage surface, and has been reported to be detri-
mental to the surrounding healthy articular cartilage6.
Alternatively, cartilage biopsies could be harvested from healthy
areas of the osteochondral defected ankle joint7. Indeed, promising
clinical results were reported when autologous chondrocytes
derived from cartilage cylinders taken from the anterior part of
talus were used to restore of full-thickness cartilage defects of such
joint4. Moreover, our recent ﬁnding that chondrocytes isolated
from ankle cartilage exhibit similar proliferation ability and post-
expansion tissue-forming capacity than chondrocytes isolated from
knee cartilage8 suggests that talar chondrocytes may represent
a suitable cell source for the repair of cartilage lesions of the talus.
The harvest of talar chondrocytes from healthy areas of defectedublished by Elsevier Ltd. All rights reserved.
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already injured joint9.
To overcome the aforementioned possible problems caused by
the harvesting of cartilage biopsies from healthy knee or healthy
areas of the already affected ankle joint, a rational and convenient
approach would be represented by the utilization of chondrocytes
isolated from already detached OCL fragments which are debrided
during surgery. In this regard, it was reported that viable cells can
be isolated from detached osteochondral fragments from human
articular joints10,11. Moreover, the implantation of such chon-
drocytes in patients was reported to yield good clinical results 12
months post-operatively11. However, the chondrogenic capacity of
cells isolated from detached OCL fragments remains controversial.
While Giannini et al.11 reported that these cells have the potential to
re-express or synthesize to a certain extent cartilage speciﬁc genes
and proteins during culture in three-dimensional (3D) porous
scaffolds, Kuroki et al.12, showed that constructs generated by
chondrocytes from naturally occurring OCL of the humeral head of
dogs and cultured in agarose gel formed tissues containing inferior
amount of glycosaminoglycan (GAG), type II collagen and hydrox-
yproline and superior amounts of type I collagen as compared to
those generated by chondrocytes from healthy cartilage. Similarly,
Garvican et al.13 found that chondrogenic differentiation of equine
chondrocytes from Damaged Ankle Cartilage Fragments (DACF)
was inferior to that of aged-matched normal chondrocytes.
The goal of this study was thus to assess the quality of carti-
laginous tissues generated by human chondrocytes harvested from
the detached fragments of OCL of ankle joints (DACF), using
chondrocytes derived from normal ankle cartilage (NAC) as control
cells. Cells were cultured in micromass pellets or in scaffolds in
clinical use for the delivery of human chondrocytes (HYAFF-11),
and the resulting tissues assessed phenotypically, biochemically
and biomechanically.
Materials and methods
Cartilage biopsies
DACF were harvested from the talus of six patients (female:
male¼ 3:3, mean age: 36, age range: 30e43 years) scheduled for
surgery of symptomatic talar OCLs of this joint (Table I), following
informed consent. Lesions, localized in the middle third of the
medial talus edge or at the lateral side, were from traumatic origin
and not associated with diagnosed instability of the ankle joint. The
mean time elapsed between the traumatic event and surgery was
6.5 months, which is typically sufﬁcient to allow for the onset of
early degenerative changes in the joints (e.g., cartilage ﬁbrillation in
the border of the lesion). The OCLs, graded according to the widely
used Berndt & Harty classiﬁcation (grades IeV; grade I: sub-
chondral compression; grade II: partially avulsed fragment; grade
III: detached but not displaced fragment; grade IV: displaced
fragments; grade V: subchondral cyst)14 were of grade III (5/6) orTable I
Patient information for OCLs
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6
Gender Female Male Male Female Male Female
Age 30 Years 43 Years 39 Years 36 Years 33 Years 37 Years
Joint side Medial Medial Lateral Medial Lateral Medial
OCL grade
(Berndt
& Harty)
III III III II III III
Interval
trauma/
operation
14 Months 3 Months 6 Months 6 Months 4 Months 6 Monthsgrade II (1/6) (Table I). During surgery the OCL fragments were
found as talar in situ dissecates, carefully harvested, and immedi-
ately sent from the operation room to the laboratory for further
analyses.
As control, NAC biopsies were harvested from the healthy areas
of the talus of 10 cadavers (female:male¼ 4:6, mean age 55, range
32e79 years) in accordance with the Local Ethical Committee8. The
chondral layers of DACF and NAC biopsies were cleaned meticu-
lously from ﬁbrous tissue and bone, and rinsed several times in
a sterile saline solution.
DACF and NAC biopsies were chopped in small pieces which
were processed in parallel for histology and immunohistochem-
istry (about 50 mg), for biochemistry (about 50 mg), or for chon-
drocyte isolation (about 100 mg) as described below.
Chondrocytes isolation and expansion
Samples derived from DACF and NAC were digested with 5 ml of
type II collagenase [0.15% in basic medium e see below e supple-
mented with 5% fetal bovine serum (FBS)] for 22 h8. The isolated
chondrocytes were counted using trypan blue, plated in tissue
culture ﬂasks at a density of 10,000 cells/cm2 and cultured for two
passages in Dulbecco’s modiﬁed Eagle’s medium (DMEM) con-
taining 4.5 mg/ml D-glucose, 0.1 mM nonessential amino acids,
1 mM sodium pyruvate, 100 mM HEPES buffer, 100 U/ml penicillin,
100 mg/ml streptomycin, and 0.29 mg/ml L-glutamine (basic
medium) supplemented with 10% FBS, 1 ng/ml of transforming
growth factor (TGF)-b1 and 5 ng/ml of ﬁbroblast growth factor-2 in
a humidiﬁed 37C/5% CO2 incubator with medium changes twice
a week, as previously described8. Expanded DACF- and NAC-
chondrocytes were harvested for mRNA analysis or subsequently
cultivated in pellets or in 3D scaffolds, according to previously
established methods and as brieﬂy described below.
Chondrocyte cultivation in pellets
The chondrogenic capacity of expanded DACF- and NAC-chon-
drocytes was investigated using a simple and broadly used model,
namely pellet cultures in a deﬁned serum-free medium14. Brieﬂy,
cells were suspended in basic medium supplemented with ITSþ1
(Sigma Chemical, St. Louis, MO; i.e., 10 mg/ml insulin, 5.5 mg/ml
transferrin, 5 ng/ml selenium, 0.5 mg/ml bovine serum albumin,
4.7 mg/ml linoleic acid), 0.1 mM ascorbic acid 2-phosphate,
1.25 mg/ml human serum albumin, 107 M dexamethasone and
10 ng/ml TGF-b1 (chondrogenic medium, CHM). Aliquots of 5105
cells/0.5 ml were centrifuged at 250g for 5 min in 1.5 ml poly-
propylene conical tubes (Sarstedt, Nümbrecht, Germany) to form
spherical pellets, which were placed onto a 3D orbital shaker
(Bioblock Scientiﬁc, Frenkendorf, Switzerland) at 30 rpm. Pellets
were cultured for 2 weeks, with medium changes twice per week,
and subsequently processed for histological and immunohisto-
chemical or biochemical analysis as described below. Each analysis
was performed independently in at least two entire pellets for each
primary culture.
Chondrocyte cultivation in 3D scaffolds
The ability of expanded DACF- and NAC-chondrocytes to
generate neo-cartilage was also investigated by cultures in esteri-
ﬁed hyaluronic acid non-woven meshes (HYAFF-11, Fidia
Advanced Biopolymers, Abano Terme, IT), currently in clinical use
for cartilage repair15 since such model allows more extensive
cartilaginous tissue maturation than in pellets over prolonged
culture times16. Chondrocytes were loaded statically on the scaf-
folds (6 mm diameter, 2 mm thick disks) at a density of
Table II
Biochemical assessment of DACF and NAC specimens
DNA
(% dry weight)
GAGs
(% dry weight)
Type I collagen
(% dry weight)
Type II collagen
(% dry weight)
DACF
Mean, 95%CI 0.09, 0.07e0.11 5.92, 4.41e6.33 6.23, 0.21e0.33 40.7, 32.1e48.2
NAC
Mean, 95%CI 0.29, 0.21e0.33 31.5, 28.1e36.9 0.21, 0.18e0.25 62.3, 57.2e69.1
P values 0.021 0.035 0.008 0.048
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basic medium supplemented with 0.1 mM ascorbic acid, 10 mg/ml
insulin and 10 ng/ml TGF-b3, with medium changes twice a week,
as previously described8. After 14 or 28 days of static culture, the
resulting tissues were analyzed histologically, immunohis-
tochemically, biochemically and biomechanically, as described
below.
Analytical methods
Proliferation rate
Cell proliferation rate was calculated as the ratio of T to log2(N/
N0), where N0 and N are the numbers of cells respectively at the
beginning and the end of the expansion phase, and T is the time
required for the expansion17.
Histological and immunohistochemical analyses
DACF and NAC tissues and engineered tissues (pellets and
constructs) were rinsed with phosphate buffered saline (PBS), ﬁxed
in 4% formalin, embedded in parafﬁn, and cross-sectioned (5 mm
thick for pellets and 7 mm thick for constructs and native tissues).
Sections were stained with Safranin-O for sulfated GAGs, with or
without additional staining with 5% Silver nitrate solution (Von
Kossa staining for mineralized matrix detection), or processed for
immunohistochemistry using antibodies against type I collagen
(Quartett, Berlin, Germany) and type II collagen (II-II6B3,
Hybridoma Bank, University of Iowa, USA) as previously
described18,19.
Biochemical analysis
DACF, NAC and engineered constructs were cut in different
pieces, part of them were lyophilized the remaining parts were
blotted dry. Specimens were ﬁrst weighed and subsequently
digested for 15 h at 56C with protease K (1.0 ml of 1 mg/ml
protease K in 50 mM Tris with 1 mM ethylenediaminetetraacetic
acid (EDTA), 1 mM iodoacetamide and 10 mg/ml pepstatin-A).
Pellets were digested with the same protocol but using 0.5 ml
protease K. GAG amounts were measured spectrophotometrically
after reaction with dimethylmethylene blue20, with chondroitin
sulfate as a standard21. The DNA amount was measured spectro-
ﬂuorometrically using the CyQUANT Kit (Molecular Probes,
Eugene, USA) following the kit’s instruction with calf thymus DNA
as a standard. GAG contents were reported as % GAG/dry weight
tissue for DACF and NAC and engineered constructs or as GAG/DNA
for pellets. DNA contents were reported as % DNA/dry weight tissue
for DACF and NAC.
For the determination of type I and II collagens, DACF, NAC and
cartilaginous constructs were ﬁrst lyophilized. The dried samples
were fully solubilized by digestion with 2 mg/ml tosylamide-2-
phenylethyl chloromethyl ketone-treated bovine pancreatic trypsin
in 50 mM TriseHCl, pH 7.6, containing 1 mM iodoacetamide, 1 mM
EDTA and 10 mg/ml pepstatin-A, using an initial incubation of 15 h
at 37C followed by a further 2 h incubation at 65C after the
addition of fresh trypsin. Samples were boiled for 15 min to inac-
tivate the enzyme22. Amounts of type II collagen were assayed by
inhibition enzyme-linked immunosorbent assay (ELISA) using
a mouse Immunoglobulin G (IgG) monoclonal antibody to dena-
tured type II collagen23. Amounts of type I collagenwere assayed by
inhibition ELISA using a rabbit anti-peptide antibody to type I
collagen22.
Real-time quantitative RT-PCR assays
RNA of expanded DACF- and NAC-chondrocytes was extracted
using Trizol (Life Technologies, Basel, Switzerland), according to the
Manufacturer’s protocol. RNA was treated with DNAse I using theDNA-freeTM Kit (Ambion, USA) and quantiﬁed spectrophotomet-
rically. cDNA was generated from 3 mg of RNA by using 500 mg/ml
random hexamers (Catalys AG, CH) and 1 ml of 50 U/ml Stra-
tascript reverse transcriptase (Stratagene, NL), in the presence of
dNTPs. PCR reactions were performed and monitored using the ABI
Prism 7700 Sequence Detection System (PerkineElmer/Applied
Biosystems, Rotkreuz, Switzerland). Cycle temperatures and times
as well as primers and probes used for the reference gene (18S
rRNA) and the genes of interest (type I collagen and type II collagen),
were as previously described24. For each cDNA sample, the
threshold cycle (Ct) value of 18Swas subtracted from the Ct value of
the target gene, to derive DCt. The levels of expression of type I and
type II collagen were calculated as 2DCt and represented in loga-
rithmic scale. Each sample was assessed at least in duplicate for
each gene of interest.
Biomechanical analysis
Mechanical tests on constructs were conducted in a standard
miniature test instrument in unconﬁned compression (Synergie
100, MTS Systems Corp., Eden Prairie, MN, USA) to measure the
equilibrium modulus (EEQ) and the pulsatile dynamic modulus
(EPD), as previously described in detail25. Brieﬂy, EEQ was deter-
mined from a linear regression of the data pairs of equilibrium
stress/incremental strain, following application of ﬁve incremental
strains of 5% and computation of the corresponding equilibrium
stress. EPD was calculated as the slope of the stress/strain curve,
after exposing specimens to ﬁve cycles of compressive loading/
unloading at 0.17 mm/s, reaching a strain of 20% and with each
strain period followed by a no-load period of time equal to that for
loading/unloading.
Statistical analysis
Each parameter is determined by the mean and the 95% conﬁ-
dence interval (95%CI) of measurements generated using cells from
six donors for the experimental group (i.e., DACF) and cells from 10
donors for the control group (i.e., NAC). Statistical analyses were
performed using the Sigma Stat software (SPSS Inc., Version13).
Differences between groups were assessed by ManneWhitney test
and considered statistically signiﬁcant when P values were lower
than 0.05.
Results
Cellular and extracellular matrix (ECM) contents in DACF and
NAC biopsies
Macroscopically, DACF appeared rough and dull. As compared to
NAC biopsies, DACF were less cellular, as evidenced by a statistically
signiﬁcant lower amount of DNA (3.0-fold). Quantitative assess-
ments of the ECM indicated that DACF contained statistically
signiﬁcant lower amounts of GAG (5.3-fold) and type II collagen
(1.5-fold) but higher amounts of type I collagen (6.2-fold) (Table II).
Histological and immunohistochemical assessments indicated that:
(1) staining for GAG and type II collagenwere faint and/or scattered
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uted in NAC, (2) staining for type I collagen was diffuse in DACF
whereas localized in the thin superﬁcial layer of NAC, (3) staining
for Von Kossa was diffuse in DACF whereas restricted at the carti-
lage-bone interface in NAC, (4) cells with ﬁbroblastic morphology
were present within the DACF but absent or localized in the thin
superﬁcial layer of NAC, (5) clusters of cells were present abun-
dantly only within the DACF (Fig. 1).
Cell yield, proliferation rate and differentiation stage of DACF- and
NAC-chondrocytes
In agreement with the DNA quantiﬁcation results, DACF yielded
statistically signiﬁcant lower number of cells as compared to NAC
(respectively 1.7 0.6105 and 3.5 0.6105 cells/100 mg of
tissues processed for cell expansion) following enzymatic digestion
of specimens.
DACF- and NAC-chondrocytes cultured in monolayers exhibited
similar elongated and spindle-shaped morphologies characteristic
of de-differentiated chondrocytes [Fig. 2(A)]. As compared to NAC-
chondrocytes, DACF-chondrocytes (1) proliferated at higher rate
(P¼ 0.48) [cells underwent respectively 7.8 (95%CI: 6.8e8.1) and
10.4 (95%CI: 8.2e12.5) doublings in 13e17 days; Fig. 2(B)] and (2)
expressed higher type I collagen (4.2-fold; P¼ 0.31) and lower type
II collagen (3.1-fold; P¼ 0.28) mRNA levels, with consequently
lower (21.6-fold) type II/type I collagen mRNA ratio [Fig. 2(C)]. The
above described trends were not, however, statistically signiﬁcant.
The extent of cell expansion within the two passages was sufﬁcient
to generate at least about 50106 cells from 100 mg biopsy, which
was sufﬁcient for the subsequent differentiation assays and would
be clinically relevant for implantation or for engineering of a carti-
lage graft.
Post-expansion chondrogenic capacity in cell pellets
Expanded DACF-chondrocytes exhibited a generally poor re-
differentiation capacity in pellet culture. Tissues generated with
this model in fact (1) resulted negatively stained for GAG (5/6) or
positively stained only in scattered regions (1/6, donor 3) and (2)
contained cells with necrotic or ﬁbroblastic appearances. Instead,
pellets generated by NAC-chondrocytes were uniformly stained for
GAG and contained cells with the typical chondrocytic round
morphology [Fig. 3(A)]. Biochemical assessment conﬁrmed
a statistically signiﬁcant lower content of GAG (2.8-fold) in pellets
generated by DACF-chondrocytes. DACF-chondrocytes from only
one donor (donor 3) accumulated GAG at levels approaching the
average ones measured for NAC-chondrocytes8 [Fig. 3(B)]. DNA
contents of pellets generated by the two cell types were similar
(less than 10% of variation between the two groups).
Immunohistochemical analysis showed that type II collagenwas
absent (5/6) or accumulated only in limited region of pellets (1/6,
donor 3) generated by DACF-chondrocytes. In contrast, pellets
generated by NAC-chondrocytes were uniformly stained for type II
collagen [Fig. 3(C)].
Tissue-forming capacity in 3D scaffolds
After 14 days of culture in HYAFF-11 meshes, tissues based on
DACF-chondrocytes were negatively stained for GAG and type II
collagen while the tissues based on NAC-chondrocytes were faintly
stained for both proteins. At the same time, tissues generated by
both DACF- and NAC-chondrocytes had similar amounts of DNA
and contained cells with ﬁbroblastic appearance (data not shown).
After 28 days of culture, tissues generated by DACF-chondrocytes
remained negatively stained for GAG (5/6) or accumulated ECMfaintly stained for GAG (1/6, donor 3) in restricted regions, and
contained predominantly ﬁbroblastic cells. At this time point,
tissues generated by DACF-chondrocytes had signiﬁcantly lower
DNA content than those generated by NAC-chondrocytes (1.5-fold),
likely indicating the reduced capacity of the former chondrocytes to
proliferate within the scaffolds. Staining for type II collagen was
negative in all constructs. Instead, tissues generated by NAC
chondrocytes accumulated large amounts of ECM positively stained
for GAG and type II collagen and contained a large fraction of cells
with a chondrocytic morphology [Fig. 4(A)].
Biochemical analysis generally conﬁrmed the histological
observations. GAG and type II collagen as a % of dry weight did not
increase from 14 to 28 days of culture in constructs based on
DACF-chondrocytes, and thus remained at statistically signiﬁcant
lower levels than those measured in constructs based on NAC-
chondrocytes (1.9- and 1.7-fold respectively). Instead, type I
collagen markedly increased with culture time (3.3-fold), result-
ing, at 28 days, in higher amounts (1.5-fold) in constructs based on
DACF-chondrocytes than in those based on NAC-chondrocytes
[Fig. 4(B)]. At the latest culture time the ratio of type II to type I
collagen was 2.9-fold higher in constructs based on NAC-
chondrocytes.
The measured biomechanical properties of tissues captured the
biochemical differences [Fig. 4(C)]. In fact, equilibrium modulus
and dynamic pulsatile modulus (1) did not signiﬁcantly increase
between 14 and 28 days of culture in constructs based on DACF-
chondrocytes, and (2) were signiﬁcantly lower in constructs based
on DACF-chondrocytes as compared to those based of NAC-
chondrocytes (1.7- and 3.3-fold respectively) after 28 days of
culture.
Discussion
In this study, chondrocytes harvested from the detached frag-
ments of OCLs of ankle joints (DACF) and from normal articular
cartilage (NAC) of the talus of cadavers were compared in terms of
their growth and de-differentiation during two-dimensional
culture, as well as of their post-expansion tissue-forming capacity.
DACF-chondrocytes displayed more ﬁbroblastic characteristics, as
evidenced by the trends of higher proliferation rate and higher
extent of de-differentiation. When induced to re-differentiate in
pellet culture or in porous scaffolds, DACF-chondrocytes produced
tissues with lower GAG and type II collagen contents and lower
biomechanical properties.
Histological and biochemical assessments of the harvested DACF
indicate that such tissues contained markedly lower amount of
proteoglycans and type II collagen and higher amounts of type I
collagen as compared to NAC. Interestingly, a large portion of the
dry weight of DACF remains unaccounted for by the measured
extracellular components and likely consisted of macromolecules
produced to a larger extent by more ﬁbroblastic cells (e.g., type III
collagen and versican) or of mineral deposits, since in fact large
areas of ﬁbrocartilage and mineralized cartilage were observed in
the DACF. Although our harvested DACF were from slightly older
patients as compared to those of Giannini et al.11 (mean age: 36.3
years and 30.5 years, respectively), our data do not support the
previously reported results11. Moreover our study is the ﬁrst to
more thoroughly compare the re-differentiation capacity of DACF-
chondrocytes to that of NAC-chondrocytes, including a biochemical
and biomechanical characterization of the in vitro generated
tissues. The ﬁndings are generally in line with those reported by
Aurich et al.10 and Garvican et al.13, describing that OCL chon-
drocytes display rather ﬁbroblastic features.
Our results clearly show that DACF-chondrocytes exhibit
a reduced re-differentiation capacity in pellets as compared to NAC-
Fig. 1. Histological appearance of detached fragments of OCLs of ankle joints (DACF) and NAC.
Safranin-O (A, B), Von Kossa/Safranin-O staining (B), type II collagen and type I collagen immunohistochemical staining (A) of DACF harvested from two different, representative
donors: donor 3 (I) and donor 5 (II) (see Table I for the donor information) and of NAC harvested from a cadaveric joint of a young individual (male, 32 years) (III). Bar¼ 100 mm.
Arrows indicate cartilage/bone interface, asterisks show cell clusters, h¼ hyaline or hyaline-like cartilage, f¼ ﬁbrocartilage, c¼ calciﬁed cartilage.
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Fig. 2. Growth and differentiation stage of chondrocytes isolated from DACF and NAC.
(A) Representative phase-contrast pictures of expanded DACF-chondrocytes (I) and NAC-chondrocytes (II) (see Table I for the donor information). Bar¼ 100 mm. (B) Proliferation rate
of DACF- and NAC-chondrocytes. Values are the mean of measurements obtained from six different DACF or 10 different NAC; error bars represent the uncertainty with a 95%CI.
(C) Real-time reverse transcriptase-polymerase chain reaction analysis of the expression of mRNA for type I (CI) and type II (CII) collagens (left y-axis labeling) or the CII/CI ratio (right
y-axis labeling). Values are the mean of measurements obtained from four different DACF or four different NAC; error bars represent the uncertainty with a 95%CI.
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type II collagen. Due to the relatively limited amount of DACF
analyzed, we could not observe clear correlations between chon-
drogenesis and either patient age or the interval between trauma
and the operation. Although the models here used to investigate
the cartilage-forming ability have been previously validated using
a variety of different chondrogenic cell types16,26, we cannot
exclude that the presence of growth factors during the phases of
cell expansion/differentiation could have critically determined the
observed differences.
Similarly to our results, Garvican et al.13 have recently found
that pellets generated by chondrocytes from equine OCL con-
tained signiﬁcantly lower GAG and expressed signiﬁcantly less
amount of So9 than pellets created from normal chondrocytes.
Interestingly in the same study the authors observed that OCL
chondrocytes expressed higher levels of MMP-13 mRNA as
compared to normal chondrocytes. Therefore, the impaired
capacity of OCL (vs normal) chondrocytes to re-differentiate could
be a consequence of both decreased synthesis and increased
degradation of ECM. The observations reported for OCL chon-
drocytes should not be generalized to other cartilage pathologies,
since it was recently demonstrated that chondrocytes from oste-
oarthritic patients display a normal chondrogenic differentiation
capacity27.
We are aware that the models used in the present study to
characterize the post-expansion chondrogenic capacity of
DACF-chondrocytes (i.e., static culture in the presence ofchondrogenic factors), have not been validated to directly
predict the reparative ability of the cell types when implanted
in the talar lesions. In a recent work, Giannini et al.28 reported
results of a clinical study in which 46 patients with focal talar
dome OCL were treated with ACI using HYAFF-11 and chon-
drocytes harvested from the detached OCL fragments or from
tissue harvested from the margin of the lesion or from the
anterior margin of the tibia. The authors however did not
describe differences in the clinical outcome of patients treated
with the different cell sources. Controlled randomized clinical
trials are therefore necessary to compare clinical outcome of
cell-based cartilage repair technique based on the DACF- and
NAC-chondrocytes.
In conclusion, our results indicate that chondrocytes isolated
from DACF have inferior cartilage-forming capacity as compared
to chondrocytes from NAC tissues, probably resulting from envi-
ronmental changes occurring during and after OCL trauma/
disease. The study opens some reservations on the use of DACF-
derived cells for the repair of ankle cartilage defects, especially in
the context of tissue engineering-based approaches, since DACF-
chondrocytes would not be able to generate functional cartilagi-
nous tissues in vitro. Further investigations are required to assess
whether the use of culture conditions including different
biochemical and biomechanical cues, or sorting of subpopulations
expressing higher levels of markers associated with the cell
chondrogenic capacity29, could enhance the cartilage-forming
ability of DACF-chondrocytes.
Fig. 3. Differentiation capacity of chondrocytes isolated from DACF and NAC in pellets.
(A) Safranin-O stainings of representative pellets generated by DACF-chondrocytes harvested from two different donors: donor 3 (I), donor 5 (II) (see Table I for the donor infor-
mation) and NAC-chondrocytes harvested from a cadaveric joint of a young individual (male, 32 years) (III) Bar¼ 100 mm. (B) Sulfate GAG content normalized to the amount of DNA
in pellets. Values are the mean of triplicate pellets; error bars describe observed variations. The plotted lines indicate mean values measured in pellets generated by cells from NAC
(upper line, 10 donors) or DACF (bottom line, six donors). (C) Type II collagen immunohistochemical stainings of representative pellets generated by DACF-chondrocytes harvested
from two different donors: donor 2 (I), donor 3 (II) and NAC-chondrocytes harvested from a cadaveric joint of a young individual (male, 32 years) (III).
C. Candrian et al. / Osteoarthritis and Cartilage 18 (2010) 1067e1076 1073
Fig. 4. Differentiation capacity of chondrocytes isolated from DACF and NAC in HYAFF-11 scaffold.
Safranin-O stainings (A) and type II collagen immunohistochemical stainings (B) of representative constructs generated by DACF-chondrocytes harvested from two different donors
[donor 3 (I), donor 5 (II) (see Table I for the donor information)] and NAC-chondrocytes harvested from a cadaveric joint of a young individual (male, 32 years) (III) cultured in CHM
for 28 days. Bar¼ 100 mm. h¼ hyaline-like cartilage, f¼ ﬁbrocartilage (C) Amounts of sulfate GAG, type I collagen and type II collagen accumulated in constructs generated by DACF-
chondrocytes (white bars, six donors) and NAC-chondrocytes (gray bars, 10 donors) expressed as a percentage of tissue dry weight; error bars represent the uncertainty with a 95%
CI. (D) Equilibrium modulus and dynamic pulsatile modulus of constructs generated by DACF-chondrocytes (white bars, six donors) and NAC-chondrocytes (gray bars, 10 donors);
error bars represent the uncertainty with a 95%CI.
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